Navigation Links
PCMA: New Legislation Would Increase Prescription Drug Costs, Limit Access
Date:5/7/2010

Independent Drugstore Lobby Seeks to Limit Fraud Detection Efforts (Again)

Washington, D.C. (Vocus) May 7, 2010 -- The Pharmaceutical Care Management Association (PCMA) released the following statement today on H.R. 5234, the PBM Audit Reform and Transparency Act of 2010, legislation championed by the independent drugstore lobby:

"Pharmacy benefit managers (PBMs) have pioneered tools – including incentivizing the use of generic medications, e-prescribing, and mail-service pharmacies – that improve savings, access, and safety for consumers and payers. Since the key to access is affordability, payers and policymakers alike should explore broader use of PBMs' cost-savings tools and reject approaches that make prescription drugs more expensive.

"The widespread use of proven PBM tools in Medicare Part D has contributed to the program's total expenditures being 43 percent lower than originally projected.

"Unfortunately, the independent drugstore lobby continues to push an agenda that increases prescription drug costs for consumers and payers and limits efforts to root out fraud, waste, and abuse. Given the increased focus on controlling health care costs, we can't afford to let anyone, including the independent pharmacy lobby, thwart congressional efforts to fight pharmacy fraud.”

In letters sent to Senate Finance Committee Ranking Member Charles Grassley (R-Iowa) and Health and Human Services (HHS) Secretary Kathleen Sebelius, PCMA outlined several proposals being pushed by the independent pharmacy lobby that could make it more difficult to root out fraud, waste, and abuse, including:

 
  • Mandating that PBMs contract with pharmacies that are currently banned from participating in federal programs.
  • Opposing the Office of Inspector General's ability to prosecute pharmacists charged with a felony.
  • Undermining the President's proposal to enhance Medicaid fraud enforcement.
  • Requiring a lengthy waiting period to remove a pharmacy from a network even with irrefutable evidence of fraud.
  • Creating unnecessary hurdles that hinder the ability of plans to audit pharmacies thoroughly.
  • Exempting independent pharmacies from routine accreditation requirements to sell Durable Medical Equipment (DME).

PCMA represents the nation's pharmacy benefit managers (PBMs), which improve affordability and quality of care through the use of electronic prescribing (e-prescribing), generic alternatives, mail-service pharmacies, and other innovative tools for 210-plus million Americans.

Follow PCMA on Twitter

Contact:
Charles Coté
202-207-3605
www.pcmanet.org

# # #

Read the full story at http://www.prweb.com/releases/PCMA/pharmacy-benefit-managers/prweb3976964.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. PCMA: Federal Enrollees Don't Want Congress to Reduce Pharmacy Choices, Impose Price Controls in FEHBP
2. PCMA: Proposed Overhaul of FEHBP Pharmacy Benefit Would Undermine Cost-Saving Tools, Reduce Choices for 8 Million Americans
3. Fitness Industry Gathers on Capitol Hill Hours After Healthy CHOICES Act is Introduced, Urging Congress to Pass Anti-Obesity, Exercise Promotion Legislation
4. Duty of Care - New Driving Legislation Could Put You in Court! UKContractHireandLeasing spread the word on these new regulations
5. Age Management Medicine Conference Reports 21% Spike in Physician Registration, Linked To Frustrations With New Health Reform Legislation
6. Hospital admissions dropped after anti-smoking legislation in place
7. Minority Businesses Support Health Care Reform Legislation, According to Survey
8. Bishops Encourage Vigilance that Health Care Legislation Protects Conscience, Does Not Fund Abortion
9. MHPA Statement on Health Reform Legislation
10. The Arc Applauds House Passage of Health Care Reform Legislation
11. Statement of Ralph B. Everett, President and CEO, Joint Center for Political and Economic Studies, on House Passage of Health Reform Legislation
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
PCMA: New Legislation Would Increase Prescription Drug Costs, Limit Access 
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort to ... treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain management ... (SCD) is a disorder of the red blood cells, which can cause episodes of ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: